CARNILISR [L-carnitine] is a naturally occurring substance required in mammalian energy metabolism. Plasma carnitine accounts only for approximately 1 % of the total body carnitine pool, with over 98% of carnitines present in the skeletal and cardiac muscles. Dialysis therapy can cause a decrease in both free carnitine and plasma acylcarnitines. Recent studies have shown that oral & intravenous L­carnitine plays an important role on anemia and cardiovascular disease in CKD patients.

CARNILISRInjection is used to recommend for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.

Mechanism of action:
In humans, carnitine plays a pivotal role in energy metabolism through the transportation of long­ chain fatty acids across the inner mitochondrial membrane and in controlling the rates of beta oxidations of long-chain fatty acids with subsequent energy production.



CARNILIS R lnjection-

ESRD Patients on Hemodialysis
The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L). Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments ( e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.


CARNILISR injection is available in 1×5 ml ampoule